skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration
According to the World Health Organisation, cardiovascular diseases, such as heart attack and stroke, are the leading cause of death globally and account for 30% of all fatalities.1 In the US alone, over 70 million adults are estimated to have high enough cholesterol levels to double their risk of heart disease2; yet numbers of new therapeutics in development for this disease area have lagged behind others such as oncology and neurology. However, an analysis of the current late stage dyslipidaemia landscape reveals that this area may be gaining traction within the industry. A few promising compounds, notably the PCSK9 inhibitors, are working their way through the pipeline, and it looks like a race to develop the next cholesterol blockbuster drug is taking shape. In this paper, we take a forensic look at this area to try to identify current trends and which near-term compounds look the most encouraging.

Highlights in this white paper include:

Although cardiovascular diseases are the leading cause of death globally, the number of new therapeutics in development for this disease area have lagged behind others such as oncology and neurology. However, analysis of the current late stage dyslipidaemia landscape reveals that this area may be gaining traction within the industry. This white paper takes a forensic look at recent developments to identify current trends and which near-term compounds look the most encouraging.

 

  • How promising compounds including PCSK9 inhibitors are working their way through the pipeline
  • The race to develop the next cholesterol blockbuster drug
  • Phase III pipeline drugs, developers and mechanisms of action
  • The most commonly reported sponsors of Phase I – III dyslipidaemia trials as reported in Citeline’s clinical trial database, Trialtrove
  • Breaking down the current set of clinical and preclinical PCSK9 inhibitors by drug type to reveal current anti-PCSK9 strategies
dyslipidaemia development
Download white paper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free   : +1 888 670 8900  
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (20) 805 20700

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now